SCHEMBL5152015

SCHEMBL5152015

Cc1cc(CC(=O)OC(C)(C)C)ccc1NC(=O)Nc1ccccc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGA4 P13612 2/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
CXCR1 P25024 4/20 0.44
ALDH1A1 P00352 2/20 0.43
RAB9A P51151 4/20 0.43
HTT P42858 3/20 0.43
NPC1 O15118 2/20 0.43
LMNA P02545 1/20 0.43
CXCR2 P25025 4/20 0.43
CYP1A2 P05177 1/20 0.42
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
NR1H4 Q96RI1 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
IDH1 O75874 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5155365 0.86 RAB9A (0.57) MEN1KMT2AALDH1A1RAB9AHTT
SCHEMBL5155477 0.86 ITGA4 (0.47) ITGA4MEN1KMT2AALDH1A1RAB9A
SCHEMBL5151870 0.86 CXCR2 (0.46) ITGA4MEN1KMT2AALDH1A1RAB9A
SCHEMBL5151950 0.85 MAPT (0.51) ITGA4MEN1KMT2AALDH1A1RAB9A
SCHEMBL5155096 0.84 POLB (0.55) ITGA4MEN1KMT2AALDH1A1RAB9A
SCHEMBL5153169 0.83 MEN1 (0.52) ITGA4MEN1KMT2ACXCR1ALDH1A1
SCHEMBL5156939 0.81 NR1H4 (0.41) ITGA4HTTLMNANR1H4
SCHEMBL6037562 0.81 ITGA4 (0.56) ITGA4MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL5151663 0.79 KMT2A (0.52) ITGA4MEN1KMT2ACXCR1ALDH1A1
SCHEMBL5151777 0.79 ITGA4 (0.50) ITGA4MEN1KMT2AALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 ITGA4 3/4885MEN1 2953/4885KMT2A 1046/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 ITGA4 4/4885MEN1 3283/4885KMT2A 735/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 ITGA4 5/4885MEN1 3022/4885KMT2A 918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.